TCT 2020 | Initial Studies Show Incredible Results with Lithotripsy in Calcified Lesions

Intravascular coronary lithotripsy shows promise for the improvement of angioplasty in severely calcified lesions, according to data from the DISRUPT CAD III study, published in JACC and simultaneously presented at the TCT 2020 Congress.

Calcification in all patients enrolled was highly severe, with an average length of 48 mm, and side-branch involvement in 30% of cases.

Lithotripsy, which involves using acoustic pressure waves to fracture calcium, was well tolerated with low rates of complications.

Observed results were confirmed by pre- and post-procedure intravascular imaging.

DISRUPT CAD III enrolled 431 patients in 47 sites presenting severely calcified de novo coronary artery lesions with reference diameters between 2.5 mm and 4.0 mm.


Read also: TCT 2020 | Fewer Symptoms and Events when Optimizing with iFR.


The primary safety endpoint was observed in 92.2% of patients. Similarly, the effectiveness endpoint occurred in 92.4%. Both endpoints exceeded expectations.

Previous reports indicated the possibility of ventricular capture with shock waves, something that was observed in this study. Said captures were not associated with sustained ventricular arrhythmias during or immediately after the procedure, and they did not correlate with adverse events either.

Conclusion

Coronary lithotripsy was safe and effective in facilitating stent implantation and expansion in highly calcified lesions.

DISRUPT-CAD-III

Original Title: Intravascular lithotripsy for treatment of severely calcified coronary artery disease: the DISRUPT CAD III study.

Reference: Hill JM et al. J Am Coll Cardiol. 2020; Epub ahead of print y presentado simultáneamente en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...